{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:46:33Z","timestamp":1789847193383,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ygyno.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T19:27:44Z","timestamp":1517513264000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Management of the toxicities of common targeted therapeutics for gynecologic cancers"],"prefix":"10.1016","volume":"148","author":[{"given":"Camille C.","family":"Gunderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.01.010_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0025","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0030","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.174","article-title":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","volume":"227","author":"Di Lisi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0055","unstructured":"FDA Package Insert for Bevacizumab."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0065","unstructured":"FDA Label for Pazopanib."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0070","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0075","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0080","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"32","author":"Burger","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0095","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.ygyno.2018.01.010_bb0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0105","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.gore.2016.06.002","article-title":"Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy?","volume":"17","author":"Corr","year":"2016","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0125","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1215\/15228517-2008-010","article-title":"What is the risk of intracranial bleeding during anti-VEGF therapy?","volume":"10","author":"Carden","year":"2008","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2012.07.004","article-title":"An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases","volume":"78","author":"Sandler","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","article-title":"Management of bevacizumab-associated bowel perforation: a case series and review of the literature","volume":"19","author":"Badgwell","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11912-012-0236-x","article-title":"Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance","volume":"14","author":"Ramiscal","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0155","first-page":"205","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"65","author":"Lee","year":"2008","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.010_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","article-title":"AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo","volume":"17","author":"Faubert","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.juro.2012.09.160","article-title":"Re: what the radiologist needs to know about urolithiasis: part 1-pathogenesis, types, assessment, and variant anatomy","volume":"189","author":"Siegel","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0185","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0190","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0240","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0250","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0265","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0270","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2018.01.010_bb0275","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A phase I\u2013II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0285","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0290","unstructured":"FDA Label for Olaparib."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0295","unstructured":"FDA Label for Rucaparib."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0300","unstructured":"FDA Label for Niraparib."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0305","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists","volume":"76","author":"de Boer-Dennert","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0310","series-title":"Clinical Practice Guidelines in Oncology: Antiemesis","author":"NCCN","year":"2017"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0320","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0325","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0330","first-page":"58","article-title":"Taste and odor abnormalities in cancer patients","volume":"7","author":"Hong","year":"2009","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0335","first-page":"129","article-title":"The dental treatment needs and oral side effects of patients undergoing outpatient cancer chemotherapy","volume":"13","author":"Wilson","year":"2005","journal-title":"Eur. J. Prosthodont. Restor. Dent."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0340","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2014mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0345","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0350","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jnci\/djt181","article-title":"Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2","volume":"105","author":"Barton","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0355","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jnci\/djn250","article-title":"A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue","volume":"100","author":"Minton","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0360","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajco.12636","article-title":"Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Friedlander","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0365","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.01.010_bb0370","unstructured":"2009."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0385","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0390","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0400","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0405","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0410","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.01.010_bb0415","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T13:34:03Z","timestamp":1535117643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818300428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0090825818300428"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of the toxicities of common targeted therapeutics for gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}